Company: RPTX
Filing Date: 2025-11-17
Form Type: DEFA14A
Source: 0001193125-25-284040
Chunk: 52

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-17
Form: DEFA14A
Chunk 52
---
 supervision over the Discontinuance. Nothing in this 
 Agreement, including any of the restrictions set forth herein, shall be interpreted in such a way as to place any Party in violation of applicable Law.                                                                                          |

| (f) | For greater certainty, nothing in this Agreement will restrict the Company or the Subsidiary from                                                                                                                                                      
 (i) incurring and paying costs and expenses in connection with the transactions contemplated by the Agreement, including all legal, accounting, financial advisory, printing and other administrative or professional fees, the fees of its            
 financial advisors, including in connection with the establishment of the Transaction Committee and the receipt and consideration of expressions of interest from persons other than the Purchaser prior to the execution of this Agreement, the       
 negotiation and settlement of this Agreement, the preparation and mailing of the Circular, the convening of the Meeting, applications for the Interim Order and Final Order, the solicitation of proxies in respect of the meeting and structuring and 
 completion of the transactions contemplated; (ii) paying, discharging, settling, satisfying, compromising, waiving, assigning or releasing any claims, rights, liabilities or obligations disclosed in Schedule 5.1(f) to the Disclosure Letter, or    
 (iii) entering into indemnification agreements with directors, officers and employees of the Company and the Subsidiary, and individuals related to such persons, provided that a copy of any such agreement is provided to the Purchaser not less     
 than five days prior to the Effective Date.                                                                                                                                                                                                            |

| 5.2 | Directors’ Obligations |

Nothing in this Agreement shall prevent the Board of Directors from complying with applicable Securities Laws and applicable Laws including, making any disclosures or taking any actions that may be required under applicable Laws (including the QBCA).

| 5.3 | Covenants of the Company Relating to the Arrangement |

| (a) | Subject to the terms and conditions of this Agreement, the Company shall, and shall cause the Subsidiary to,                                                                                                                                             
 perform all obligations reasonably required to be performed by the Company or the Subsidiary under this Agreement, reasonably cooperate with the Purchaser in connection therewith, and do all such other commercially reasonable acts and things as may 
 be necessary or desirable to consummate and make effective, as soon as reasonably practicable, the transactions contemplated by this Agreement and, without limiting the generality of the foregoing, the Company shall and, where appropriate, shall    
 cause the Subsidiary to: